GRIN Therapeutics is at the forefront of developing targeted therapies for rare, severe neurodevelopmental disorders.
GRIN Therapeutics has raised $140.0M in total funding. The most recent round was Series D. The last funding was announced in May 2025.
GRIN Therapeutics's investors include Blackstone Life Sciences, Angelini Pharma.
GRIN Therapeutics is headquartered in New York, United States.
GRIN Therapeutics is at the forefront of developing targeted therapies for rare, severe neurodevelopmental disorders.
GRIN Therapeutics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GRIN Therapeutics — Funding & Investors." VCBacked, May 27, 2025, https://www.vcbacked.co/company/grin-therapeutics. Accessed August 15, 2026.
VCBacked. (2025). GRIN Therapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/grin-therapeutics
{{cite web |title=GRIN Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/grin-therapeutics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated